13-valent pneumococcal conjugate vaccine: A review of its use in infants, children, and adolescents

Pediatric Drugs

Volumn 15, Issue 5, 2013, Pages 403-423

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885612415     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0047-z     Document Type: Article

References (94)

1. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med. 2010;16(3):217-25.
2. O'Brien KL, Wolfson LJ, Watt JP, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893-902.
3. Pittet LF, Posfay-Barbe KM. Pneumococcal vaccines for children: a global public health priority. Clin Microbiol Infect. 2012;18(Suppl 5):25-36.
4. World Health Organization. Pneumococcal disease. www.who.int/ith/ diseases/pneumococcal/en/index.html. Accessed 27 Jun 2013.
5. Farha T, Thomson AH. The burden of pneumonia in children in the developed world. Paediatr Respir Rev. 2005;6(2):76-82.
6. World Health Organization. Acute respiratory infections (update September 2009). http://www.who.int/vaccine-research/diseases/ari/en/print.html. Accessed 28 Mar 2013.
7. European Medicines Agency. Assessment report for Prevenar 13 [online]. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/001104/WC500057250.pdf. Accessed 6 May 2013.
8. Fitzwater SP, Chandran A, Santosham M, et al. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31(5):501-8.
9. Shea KM, Weycker D, Stevenson AE, et al. Modeling the decline in pneumococcal acute otitis media following the introduction of pneumococcal conjugate vaccines in the US. Vaccine. 2011;29(45):8042-8.
10. Kellner JD. Update on the success of the pneumococcal conjugate vaccine. Paediatr Child Health. 2011;16(4):233-40.
11. Johnson DR, D'Onise K, Holland RA, et al. Pneumococcal disease in South Australia: vaccine success but no time for complacency. Vaccine. 2012;30(12):2206-11.
12. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737-46.
13. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.
14. Ben-Shimol S, Greenberg D, Givon-Lavi N, et al. Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel. Vaccine. 2012;30(46):6600-7.
15. Kaplan SL, Barson WJ, Lin PL, et al. Serotype 19A is the most common serotype causing invasive pneumococcal infections in children. Pediatrics. 2010;125(3):429-36.
16. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14(3):e197-209.
17. Weil-Olivier C, van der Linden M, de Schutter I, et al. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis. 2012;12:207.
18. Lin T-Y, Shah NK, Brooks D, et al. Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region. Vaccine. 2010;28(48):7589-605.
19. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3):244-56.
20. Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010;28(26):4249-59.
21. Fenoll A, Aguilar L, Vicioso M-D, et al. Increase in serotype 19A prevalence and amoxicillin non-susceptibility among paediatric Streptococcus pneumoniae isolates from middle ear fluid in a passive laboratory-based surveillance in Spain, 1997-2009. BMC Infect Dis. 2011;11:239.
22. CDC. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. Morb Mortal Wkly Rep. 2010;59(9):253-7.
23. Wroe PC, Lee GM, Finkelstein JA, et al. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J. 2012;31(3):249-54.
24. Sharma D, Baughman W, Holst A, et al. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr Infect Dis J. 2013;32(2):196.
25. Wyeth Pharmaceuticals Inc. Summary of product characteristics (Prevenar 13 suspension for injection). http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/001104/WC500057247.pdf. Accessed 3 May 2013.
26. Wyeth Pharmaceuticals Inc. Prescribing information Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 protein]). 2013. http://labeling.pfizer.com/showlabeling.aspx?id=501. Accessed 28 March.
27. Duggan ST. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [Prevenar 13]. Drugs. 2010;70(15):1973-86.
28. Pfizer receives European approval to expand use of Prevenar 13 to adults aged 18 to 49 years for the prevention of invasive pneumococcal disease [media release]. 2013 July 10. http://press.pfizer.com/print/node/2746. Accessed 14 Aug 2013.
29. World Health Organization. Recommendations to assure the quality, safety and efficacy of pneumococcal conjugate vaccines [online]. 2010. http://www.who.int/biologicals/areas/vaccines/pneumo/Pneumo-final-23APRIL-2010. pdf. Accessed 6 May 2013.
30. Frenck Jr R, Thompson A, Senders S, et al. 13-valent pneumococcal conjugate vaccine in older children and teens either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine [abstract no. 313 plus poster]. 8th International Symposium on Pneumococci and Pneumococcal Diseases, Iguaçu Falls, Brazil; 11-15 March 2012.
31. De Montalembert M, Abboud MR, Fiquet A, et al. A 2-dose schedule of 13-valent pneumococcal conjugate vaccine (PCV13) given to children with sickle cell disease previously immunized with 23-valent pneumococcal polysaccharide vaccine (PPSV23): results of a phase 3 study [abstract no. 3212]. Blood. 2012;120(Suppl):21.
32. Yeh SH, Gurtman A, Hurley DC, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493-505.
33. Weckx LY, Thompson A, Berezin EN, et al. A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. Vaccine. 2012;30(52):7566-72.
34. Huang L-M, Lin T-Y, Juergens C. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan. Vaccine. 2012;30(12):2054-9.
35. Kim DS, Shin SH, Lee HJ, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to Korean children receiving routine pediatric vaccines. Pediatr Infect Dis J. 2012;32(3):266-73.
36. Bryant KA, Block SL, Baker SA, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010;125(5):866-75.
37. Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28(25):4192-203.
38. Vanderkooi OG, Scheifele DW, Girgenti D, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31(1):72-7.
39. Martinon-Torres F, Gimenez-Sanchez F, Gurtman A, et al. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety. Pediatr Infect Dis J. 2012;31(4):392-9.
40. Jodar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine. 2003;21(23):3265-72.
41. Feavers I, Knezevic I, Powell M, et al. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine. 2009;27(28):3681-8.
42. Cooper D, Yu X, Sidhu M, et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29(41):7207-11.
43. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17(6):1017-26.
44. Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29(12):e80-90.
45. Frenck R Jr, Thompson A, Yeh SH, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in children previously immunized with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30(12):1086-91.
46. Grimprel E, Laudat F, Patterson S, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. Vaccine. 2011;29(52):9675-83.
47. Silfverdal SA, Flodmark CE, Rombo L, et al. 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial. Vaccine. 2013;31(9):1284-92.
48. Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127-31.
49. van der Linden M, Imohl M. Effects of 3 years of immunization with higher valent pneumococcal conjugate vaccines in German children [abstract plus poster]. 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; Milan; 28 May-1 Jun 2013.
50. Singleton R, Wenger J, Klejka JA, et al. The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr Infect Dis J. 2013;32:257-63.
51. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32(3):203-7.
52. Richter SS, Heilmann KP, Dohrn CL, et al. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. Emerg Infect Dis. 2013;19(7):1074-83.
53. Angoulvant F, Levy C, Varon E, et al. Pneumococcal pneumonia in children: a French prospective study in the era of 13 valent pneumococcal conjugate vaccines implementation in France [poster]. 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; Milan; 28 May-1 Jun 2013.
54. Diel M, Laurenz M, Krause K, et al. Impact of pneumococcal conjugate vaccines on acute otitis media among children in Germany [abstract plus poster]. 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; Milan; 28 May-1 Jun 2013.
55. Diel M, Laurenz M, Krause K, et al. Impact of pneumococcal conjugate vaccines on pneumonia among children in Germany [poster]. 31st Annual Meeting of the European Society for Paediatric Infectious Diseases; Milan; 28 May-1 Jun 2013.
56. O'Brien KL. PCV13 impact evaluations: the obvious and the unpredicted. Pediatr Infect Dis J. 2013;32(3):264-5.
57. Choi YH, Jit M, Flasche S, et al. Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales. PLoS ONE. 2012;7(7):e39927.
58. Strutton DR, Farkouh RA, Rubin JL, et al. Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data. BMC Infect Dis. 2012;12:175.
59. Link-Gelles R, Taylor T, Moore MR. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. Vaccine. 2013;31(22):2572-7.
60. Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012;31(3):297-301.
61. Gurtman A, Tansey SP, Thompson A, et al. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries [abstract]. 28th Annual Meeting of the European Society for Paediatric Infectious Diseases; Nice; 4-8 May 2010.
62. Tseng HF, Sy LS, Liu IL, et al. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013;31(22):2578-83.
63. van Hoek AJ, Choi YH, Trotter C, et al. The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. Vaccine. 2012;30:7205-13.
64. Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28:7634-43.
65. Rozenbaum MH, Sanders EAM, van Hoek AJ, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340:c2509.
66. Strutton DR, Farkouh RA, Earnshaw SR, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and the Netherlands. J Infect. 2012;64:54-67.
67. Díez-Domingo J, Ridao-Lopez M, Gutierrez-Gimeno MV, et al. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine. 2011;29:9640-8.
68. Boccalini S, Azzari C, Resti M, et al. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy. Vaccine. 2011;29:9521-8.
69. Blank PR, Szucs TD. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland. Vaccine. 2012;30:4267-75.
70. By A, Sobocki P, Forsgren A, et al. Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model. Clin Ther. 2012;34(1):177-89.
71. Klok RM, Lindkvist RM, Ekelund M, et al. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Clin Ther. 2013;35(2):119-34.
72. Robberstad B, Frostad CR, Akselsen PE, et al. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine. 2011;29(47):8564-74.
73. Bakir M, Turel O, Topachevskyi O. Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model. BMC Health Serv Res. 2012;12:386.
74. Hoshi S, Kondo M, Okubo I. Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan. Vaccine. 2013;31:2762-71.
75. Newall AT, Creighton P, Philp DJ, et al. The potential cost-effectiveness of infant pneumococcal vaccines in Australia. Vaccine. 2011;29:8077-85.
76. Chuck AW, Jacobs P, Tyrrell G, et al. Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccines. Vaccine. 2010;28:5485-90.
77. Earnshaw SR, McDade CL, Zanotti G, et al. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. BMC Infect Dis. 2012;12:101.
78. Uruena A, Pippo T, Betelu MS, et al. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine. 2011;29:4963-72.
79. Castaneda-Orjuela C, Alvis-Guzman N, Velandia-Gonzalez M, et al. Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children. Vaccine. 2012;30:1936-43.
80. Tyo KR, Rosen MM, Zeng W, et al. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine. 2011;29:6686-94.
81. Kulpeng W, Leelahavarong P, Rattanavipapong W, et al. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine. 2013;31:2839-47.
82. Wu DB-C, Chang C-J, Huang Y-C, et al. Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach. Value Health. 2012;15(1 Suppl):S15-9.
83. Lee KKC, Wu DBC, Topachevskyi O, et al. The health economic impact of universal infant vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as compared with 13-valent pneumococcal conjugate vaccine in Hong Kong. Value Health Reg Iss. 2013;2:64-74.
84. Prymula R, Kriz P, Kaliskova E, et al. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine. 2009;28(1):71-8.
85. van den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis. 2013;56(3):e30-9.
86. Prymula R, Hanovcova I, Splino M, et al. Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine. 2011;29(10):1959-67.
87. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006;367(9512):740-8.
88. Stoecker C, Hampton LM, Link-Gelles R, et al. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics. 2013;132(2):e324-32.
89. Pfizer Inc. Pfizer signs new agreement with UNICEF to supply a total of up to 740 million doses of Prevenar 13 for the world's poorest countries through 2025 [media release]. 2013. http://www.pfizer.com. Accessed 12 Aug 2013.
90. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17-24.
91. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23). Pediatrics. 2010;126(1):186-90.
92. CDC. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. Morb Mortal Wkly Rep. 2010;59(9):258-61.
93. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495-502.
94. Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381(9862):214-22.